SCHEMBL1625341

SCHEMBL1625341

CC(O)c1ccc(I)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.45
NOS1 P29475 1/20 0.45
UGT2B7 P16662 1/20 0.43
ACACB O00763 1/20 0.41
ALDH1A1 P00352 1/20 0.41
PTPN5 P54829 1/20 0.37
PGR P06401 1/20 0.36
ESR1 P03372 1/20 0.36
PDCD1 Q15116 1/20 0.36
ESR2 Q92731 1/20 0.36
CD274 Q9NZQ7 1/20 0.36
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
TPMT P51580 1/20 0.35
GSK3B P49841 1/20 0.34
APEX1 P27695 1/20 0.34
PMP22 Q01453 1/20 0.34
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
NOX1 Q9Y5S8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12812583 1.00 NOS3 (0.45) NOS3NOS1UGT2B7ACACBALDH1A1
SCHEMBL4867593 1.00 NOS3 (0.45) NOS3NOS1UGT2B7ACACBALDH1A1
SCHEMBL9331190 0.85 NOS3 (0.54) NOS3NOS1UGT2B7ALDH1A1PTPN5
SCHEMBL9331061 0.85 NOS3 (0.54) NOS3NOS1UGT2B7ALDH1A1PTPN5
SCHEMBL9331652 0.85 NOS3 (0.54) NOS3NOS1UGT2B7ALDH1A1PTPN5
SCHEMBL40655 0.85 NOS3 (0.54) NOS3NOS1UGT2B7ALDH1A1PTPN5
SCHEMBL663810 0.79 ACACB (0.39) ACACBALDH1A1CYP2D6APEX1
SCHEMBL672518 0.77 ESR1 (0.52) ACACBESR1PDCD1ESR2CD274
SCHEMBL10714 0.77 TYR (0.46) ACACBCYP1A2CYP2D6
SCHEMBL21708803 0.77 TPMT (0.38) ACACBTPMTGSK3BCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260000642-A1 PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS TAY THERAPEUTICS LTD (GB) 2026-01-01 US disclosed
US-20250353829-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS INC (US) 2025-11-20 US disclosed
US-20250263370-A1 PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS Tay Therapeutics Limited (GB) 2025-08-21 US disclosed
EP-4558224-A1 PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS Tay Therapeutics Limited (GB) 2025-05-28 EP disclosed
US-20250136580-A1 INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2025-05-01 US disclosed
US-12215093-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2025-02-04 US disclosed
EP-3781550-B1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS INC (US) 2024-10-30 EP disclosed
WO-2024150553-A1 RADIATION-SENSITIVE COMPOSITION, METHOD FOR FORMING RESIST PATTERN, AND COMPOUND JSR株式会社 2024-07-18 WO disclosed
US-20240150316-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2024-05-09 US disclosed
CN-112313208-B Bicyclic carboxamides and methods of use thereof 泰普斯特医疗公司 2024-04-19 CN disclosed
WO-2003086371-A2 USE OF EP4 RECEPTOR LIGANDS IN THE TREATMENT OF IL-6 INVOLVED DISEASES PFIZER JAPAN INC. (JP) 2003-10-23 WO disclosed
EP-1326606-A2 EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS PFIZER PHARMACEUTICALS INC. (JP) 2003-07-16 EP disclosed
EP-1326864-A2 ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS PFIZER PHARMACEUTICALS INC. (JP) 2003-07-16 EP disclosed
US-20020107273-A1 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents ASKAT INC. (JP) 2002-08-08 US disclosed
US-20020077329-A1 EP4 receptor inhibitors to treat rheumatoid arthritis PFIZER PHARMACEUTICALS INC. (JP) 2002-06-20 US disclosed
WO-2002032422-A2 EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS PFIZER PHARMACEUTICALS INC. (JP) 2002-04-25 WO disclosed
WO-2002032900-A2 ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS PFIZER PHARMACEUTICALS INC. (JP) 2002-04-25 WO disclosed
US-4185992-A Imidazole derivatives MAY & BAKER LIMITED (GB) 1980-01-29 US disclosed
US-4175544-A X-RAYS OF BODY FOR MEDICAL DIAGNOSIS Lafayette Pharmacal Inc. (US) 1979-11-27 US disclosed
US-4022814-A Iodine containing organic carbonates for use as radiographic agents LAFAYETTE PHARMACAL, INC. (US) 1977-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150316-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 NOS3 2121/4885NOS1 3363/4885UGT2B7 2065/4885
US-20020107273-A1 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents PTGS1, PTGS2, OPRM1 NOS3 715/4885NOS1 848/4885UGT2B7 178/4885
US-20260000642-A1 PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS BET1, BRD4, PHKB NOS3 1492/4885NOS1 1272/4885UGT2B7 3943/4885
US-20250353829-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 NOS3 2121/4885NOS1 3363/4885UGT2B7 2065/4885
US-20250263370-A1 PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS BET1, PHKB, BRD4 NOS3 1457/4885NOS1 1456/4885UGT2B7 4514/4885
US-20020077329-A1 EP4 receptor inhibitors to treat rheumatoid arthritis PTGER4, PTGER1, PTGER2 NOS3 2157/4885NOS1 2724/4885UGT2B7 1680/4885
US-12215093-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 NOS3 2121/4885NOS1 3363/4885UGT2B7 2065/4885
US-20250136580-A1 INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE MELK, HIPK1, HIPK3 NOS3 3000/4885NOS1 3481/4885UGT2B7 3915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.